Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06238765 · ClinicalTrials.gov registry record
CorEvitas International Adolescent Atopic Dermatitis (AD) Drug Safety and Effectiveness Registry
A clinical trial of Atopic Dermatitis, sponsored by CorEvitas.
- Recruiting
- Registry status
- 1,500
- Enrollment target
- 1
- Study location
NCT06238765 is a study of Atopic Dermatitis that is actively recruiting participants, run by CorEvitas. The registered enrollment target is 1,500 participants, above the 599-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (150% higher). The trial reports 1 study location across 1 state.
The verdict
NCT06238765, a study of Atopic Dermatitis, is actively recruiting participants, sponsored by CorEvitas.
- RECRUITING
- Registry status
- 1,500 participants
- Enrollment target
- 1
- Study location
Study Summary
Prospective observational registry for an adolescent cohort with AD under the care of a dermatology provider. Approximately 1500 subjects and 75 clinical sites in North America and select European countries will be recruited to participate with no defined upper limit for either target.
Conditions Studied
Study Locations (1)
Massachusetts
- CorEvitas, LLC - Waltham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,500 participants |
| Start Date | 2023-12-02 |
| Est. Completion | 2099-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06238765
The ClinicalTrials.gov registry entry for NCT06238765 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 1,500 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 599-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (150% higher). The listed sponsor is CorEvitas, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Atopic Dermatitis appearing as the primary indexed condition, and to 0 interventions.
NCT06238765 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06238765 about?
NCT06238765 is a clinical study titled "CorEvitas International Adolescent Atopic Dermatitis (AD) Drug Safety and Effectiveness Registry". Prospective observational registry for an adolescent cohort with AD under the care of a dermatology provider. Approximately 1500 subjects and 75 clinical sites in North America and select European countries will be recruited to participate with no defined upper limit for either target.
What is the current status of trial NCT06238765?
This trial is currently recruiting. The enrollment target is 1,500 participants. The study started on 2023-12-02. Estimated completion is 2099-12-31.
What conditions does trial NCT06238765 study?
This clinical trial studies the following conditions: Atopic Dermatitis.
Who is sponsoring clinical trial NCT06238765?
This trial is sponsored by CorEvitas, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06238765 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atopic Dermatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Registry for Systemic Eczema Treatments
RECRUITING
-
An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis (AD)
RECRUITING
-
An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis Exposed to Ruxolitinib Cream Versus Topical Corticosteroids During Pregnancy: A US Claims Database Analysis
RECRUITING
-
A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
RECRUITING · Phase 2
-
Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis
RECRUITING · Phase 1
-
Using Dupilumab to Improve Circadian Function, Sleep and Pruritus in Children With Moderate/Severe Atopic Dermatitis
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.